Visit us at booth# 4B47 during the 48th annual meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany and meet with a Siemens representative to discuss how Siemens point-of-care analyzers support HbA1c control and early detection of kidney disease. The exhibition hall is open between Tuesday, October 2 and Friday, October 5, 2012. Please go to the conference website for further information.
DCA Vantage® Analyzer
Siemens DCA Vantage® Analyzer delivers immediate dual1 HbA1c measures, eAG2, Albumin, Creatinine, and A:C ratio results along with HbA1c patient trend graphs and includes an onboard GFR calculator. Used by 75% of doctors who perform HHbA1c testing in the office3, it is one of just two HbA1c analyzers to meet NGSP’s tightened performance criteria4. Its powerful connectivity and data management features support transfer of patient results into electronic medical record and interface to hospital network.
CLINITEK Status®+ Analyzer
The CLINITEK Status+ Analyzer is an easy-to-use, automated analyzer designed to deliver quick, accurate, reliable results. The analyzer automatically calculates albumin-to-creatinine (A:C) and protein-to-creatinine (P:C) ratios for early kidney disease detection, reducing the need for 24-hour urine collection. With a broad test menu that includes Multistix® 10 SG, CLINITEK® Microalbumin 2, and CLINITEK® Microalbumin 95 test strips specifically for early kidney disease detection and management, the analyzer reinforces the CLINITEK legacy of innovation in urinalysis testing.
%HbA1c or IFCC (mmol/mol)
Not available in the U.S. Product availability varies by country.
GHX Market Intelligence, market data report. Q3 2009 Raw Data File.
2Lenters-Westra E, Slingerland RJ. Clin Chem 2010;56(1):44.
Not available in all countries.